NSCLC avancé ou métastatique
Any number of prior treatments
Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC) + cyclophosphamide + SOC treatment
Only patients receiving the maintenance/continuation of SOC treatment options mentioned below are permitted to enter the study.
To determine the feasibility and safety of DC vaccine (autologous moDCs pulsed with NeoAg peptides [PEP-DC]) given in combination with low dose cyclophosphamide in patients with advanced or metastatic NSCLC who do not show progression after SOC therapy.
Inclusion criteria at screening
Exclusion criteria at screening